Fig. 2From: Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CTThe [68Ga]Ga-PSMA-11 PET/CT images of a 63Â years old patient who received cabazitaxel following goserelin and docetaxel before (a) and after (b) therapy. Despite decreasing of serum PSA from 382Â ng/ml to 236Â ng/dl and considering the patient in biochemically stable group, new metastatic abdominal paraaortic lymph nodes and bone lesions were detected and [68Â Ga]Ga-PSMA-11 uptakes of those were increased significantly (arrows)Back to article page